Medicine composition having weight reducing function and containing orlistat

A technology of orlistat and composition, which is applied in the field of pharmaceutical composition with weight loss function, can solve problems such as unsatisfactory weight loss effect, increased defecation, fecal incontinence, etc., and achieve significant weight loss effect, low side effects, and weight loss effect

Active Publication Date: 2017-07-07
ZHONGSHAN WANHAN PHARM CO LTD
View PDF3 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, because orlistat mainly acts on the digestive tract, long-term use will cause a series of adverse reactions in the gastrointestinal tract, such as oily spots, flatulence, stool urgency, fatty (oily) cases, steatorrhea, etc. , increased bowel movements, fecal incontinence, etc.
In addition, domestic and foreign literatures all believe that after taking orlistat, the weight of overweight and obese patients can only be moderately reduced, and the weight loss effect is not satisfactory.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition having weight reducing function and containing orlistat
  • Medicine composition having weight reducing function and containing orlistat
  • Medicine composition having weight reducing function and containing orlistat

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Embodiment 1 Preparation of the pharmaceutical composition capsule with weight loss function containing orlistat

[0022] Prescription design (based on 1000 capsules):

[0023]

[0024]

[0025] Preparation:

[0026] Sodium dodecyl sulfate (SDS), povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat powder, resveratrol, and fructooligosaccharides were all passed through an 80-mesh sieve before use. Weigh sodium lauryl sulfate, povidone K30, sodium carboxymethyl starch, microcrystalline cellulose, orlistat powder, resveratrol, and fructooligosaccharides according to the prescription amount, and first add a small amount of dodecane Sodium sulfate, povidone K30, and sodium starch glycolate were mixed evenly, then microcrystalline cellulose, orlistat, resveratrol, and fructooligosaccharides were added, mixed evenly, and passed through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder to make...

Embodiment 2

[0027] Embodiment 2 Preparation of the pharmaceutical composition capsule with weight loss function containing orlistat

[0028] Prescription design (based on 1000 capsules):

[0029]

[0030]

[0031] Preparation:

[0032] Sodium dodecyl sulfate (SDS), povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat powder, resveratrol, and xylooligosaccharides were all passed through an 80-mesh sieve before use. Weigh sodium lauryl sulfate, povidone K30, sodium carboxymethyl starch, microcrystalline cellulose, orlistat powder, resveratrol, and xylooligosaccharide according to the prescription amount, and first weigh the less than twelve Alkyl sodium sulfate, povidone K30, and sodium starch glycolate are mixed evenly, then microcrystalline cellulose, orlistat, resveratrol, and xylooligosaccharide are added, mixed evenly, and passed through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder to make soft ma...

Embodiment 3

[0033] Embodiment 3 Preparation of the pharmaceutical composition capsule with weight loss function containing orlistat

[0034] Prescription design (based on 1000 capsules):

[0035]

[0036]

[0037] Preparation:

[0038] Sodium dodecyl sulfate (SDS), povidone K30, sodium starch glycolate, microcrystalline cellulose, orlistat powder, resveratrol, and soybean oligosaccharides were all passed through an 80-mesh sieve before use. Weigh sodium lauryl sulfate, povidone K30, sodium carboxymethyl starch, microcrystalline cellulose, orlistat powder, resveratrol, and soybean oligosaccharides according to the prescription amount, and first weigh the less than twelve Sodium alkyl sulfate, povidone K30, and sodium starch glycolate are mixed evenly, then microcrystalline cellulose, orlistat, resveratrol, and soybean oligosaccharides are added, mixed evenly, and passed through an 80-mesh sieve twice. Slowly add 50% ethanol solution containing 10% povidone K30 to the mixed powder t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a medicine composition having a weight reducing function and containing orlistat. The medicine composition contains orlistat, resveratrol and oligosaccharide, wherein a weight ratio of the orlistat to the resveratrol to the oligosaccharide is 1 to (0.42 to 3.75) to (0.1 to 0.6). The low dose of orlistat (one third of a conventional dose) and high dose of resveratrol are combined with any dose (high, medium, low) of oligosaccharide to use, a significant weight reducing effect can be produced for nutritional obesity mice, the weight reducing effect is better than that of the conventional dose of orlistat, and the adverse reaction morbidity of gastrointestinal tract is lower than that of the conventional dose of orlistat. The medicine composition is a health weight reducing drug with low side effect and meets the requirement of modern people on the weight reducing drugs.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to a pharmaceutical composition containing orlistat and having the function of reducing weight. Background technique [0002] With the rapid development of social economy and continuous improvement of people's living standards, great changes have taken place in people's diet structure, and the problem of obesity has become more and more serious. Obesity is a metabolic disease caused by the imbalance of the body's energy budget. It is mainly a chronic metabolic disease caused by people's bad eating habits, living habits, and environmental and genetic factors. It is also a disease of hypertension, diabetes, dyslipidemia, coronary heart disease, etc. , myocardial infarction and other risk factors for many diseases, the World Health Organization is rated as the fifth largest risk factor affecting human health. [0003] In recent years, due to people's life pressure, fast pace and la...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7016A61K31/702A61K31/733A61K31/715A61K31/365A61K31/05A61P3/04
CPCA61K31/05A61K31/365A61K31/7016A61K31/702A61K31/715A61K31/733A61K2300/00
Inventor 向飞杜志博徐小林彭韪
Owner ZHONGSHAN WANHAN PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap